The generic pharmaceutical company Alvogen Inc. (Parsippany, N.J.) introduces the AB-1 rated Nitroglycerin Transdermal Delivery System, which is available in patient-ready, 30-count cartons and includes several key packaging features designed to improve care. Some of these features are RSS barcoding on each individual unit; the smallest available patch sizes of any generic nitroglycerin system; and hypoallergenic, transparent patches.
Tapemark (West St. Paul, MN) is pleased to announce the promotion of Pat Mork to vice president, human resources. In her previous role as director of human resources, she was responsible for the successful oversight in the application of over $750,000 of training for Tapemark employees, supported by a three-year Minnesota Job Skills Partnership grant. Additionally Pat led the establishment of an employee-driven wellness committee that is having a significant impact on the overall health of the Tapemark employee population.
Valeritas Inc.'s V-Go Disposable Insulin Delivery Device provides Type 2 diabetic patients with a simple option for basal-bolus insulin therapy. The medical technology company, which is committed to the development and commercialization of innovative drug delivery solutions, announced that the U.S.
Manufacturer-prepared, premixed ready-to-use products represent a preferred approach to advance initiatives and professional standards for improving intravenous drug safety. Organizations that promote, support, and monitor implementation of practices intended to assure quality services in the hospital environment include the Joint Commission, the United States Pharmacopeia, and the American Society of Health System Pharmacists.
Actavis Inc. (Morristown, NJ) announced a voluntary recall to the wholesale and retail levels only of 18 lots of Fentanyl Transdermal System 25 mcg/hour C-II patches manufactured for Actavis by Corium International in the United States.
By Marie Redding
Delivering Flu Vaccinations
In recent years, Becton, Dickinson, and Co. (Franklin Lakes, NJ) and Sanofi Pasteur joined efforts, collaborating to commercialize the first prefilled influenza vaccine utilizing a novel microinjection system for intradermal delivery. BD began developing the technology more than 10 years ago.
When the World Health Organization declared the H1N1 pandemic in June 2009, Novartis was already busy preparing seasonal influenza vaccines for the 2009–2010 season. “We typically prepare 70–80 million doses for a typical season,” explains Matt Stober of Novartis Technical Operations. “We had to ramp up quickly to be able to provide an additional 150 million doses of H1N1.” In total, Novartis produced over 200 million influenza vaccines.
West Pharmaceutical Services Inc. and Grifols USA L.L.C. announce the availability of West’s Mix2Vial filtered transfer system for the reconstitution of Grifols’ coagulation therapies. The Mix2Vial system, developed and manufactured by West’s subsidiary Medimop Medical Projects Ltd., is a patented device designed for easy reconstitution of lyophilized drugs.
Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Oramed's Oral Insulin Capsules
JERUSALEM, Israel, July 7, 2010/PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, today announced that Oramed entered into a Manufacturing Supply Agreement (MSA) with sanofi-aventis. According to the MSA, sanofi-aventis will supply Oramed with specified quantities of recombinant human insulin to be used by Oramed for its clinical trials in the USA.